# A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

> **NCT01349036** · PHASE2 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 38 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** PLX3397

## Key facts

- **NCT ID:** NCT01349036
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12-03
- **Primary completion:** 2013-11-05
- **Final completion:** 2013-11-05
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2020-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349036, "A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01349036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*